



## P&T Committee Meeting Minutes

|  |  |
|--|--|
| <b>Subject:</b>                            | Louisiana Department of Health<br>Medicaid Pharmaceutical and Therapeutic Committee Meeting  |
| <b>Location:</b>                           | 628 North Fourth Street<br>Baton Rouge, LA<br>Bienville Building<br>Room 118   |
| <b>Date:</b>                               | November 2, 2018   |
| <b>Members Present:</b>                    | <ul style="list-style-type: none"><li>▪ Dr. Tamer Acikalin</li><li>▪ Dr. Marcus Bachhuber</li><li>▪ Dr. Jill Comeau</li><li>▪ Dr. Donald (Chancellor)</li><li>▪ Fred Mills (Senator)</li><li>▪ Dr. David Mushatt</li><li>▪ Ben Orlando RPh</li><li>▪ J. Rogers Pope (Representative)</li><li>▪ Dr. Ed Walker</li><li>▪ Marty R. McKay, RPh</li></ul> |
| <b>DHH Pharmacy Program Staff Present:</b> | <ul style="list-style-type: none"><li>▪ Melwyn Wendt, PharmD</li><li>▪ Germaine Becks-Moody, PhD, BHSF</li><li>▪ Sue Fontenot, RPh</li><li>▪ Paul Knecht, MS, PharmD</li><li>▪ Ms. Haley Williams</li><li>▪ April Holley PharmD, MBA</li></ul>   |

|                             |  |
|-----------------------------|--|
| <b>Contractors Present:</b> | <ul style="list-style-type: none"> <li>▪ Douglas Brown RPh, MBA, Magellan Medicaid Administration</li> <li>▪ Hind Douiki, PharmD, Magellan Medicaid Administration</li> <li>▪ Kristina Carter, Certified Court Reporter</li> </ul> |
| <b>Others Present:</b>      | Presenters are listed in the minutes and sign in sheets and others in attendance from DHH, Bureau of Health Services Financing, Pharmacy Benefits Section upon request.  |

### Call to Order

Marty R. McKay, Chairman, called the meeting to order at or around 9:08 a.m. after a quorum was reached with 10 members. He stated that this meeting will be conducted in compliance with the Open Meetings Law.

### Parliamentary Business

- A. Additional Agenda Items.** The Chair entertained requests for additional agenda items. Hearing none, Mr. McKay stated that the posted agenda will be adopted. He also asked for a motion from the members to have the ability to reorder the agenda as they see fit. Mr. Orlando made a motion to accept; Dr. Comeau seconded it.
- B. Introduction of Members.** Committee members, staff, and contractors introduced themselves.
- C. Announcement of Election of Officers – Chair and Co-Chair Elections.** Mr. Orlando nominated Marty McKay as Chair; senator Mills seconded it. Mr. Orlando nominated Dr. Comeau as Co-Chair; Dr. Comeau respectfully declined. Mr. McKay nominated Mr. Orlando as Co-Chair; senator Mills seconded it.
- D. Approval of Minutes.** Mr. McKay asked for a motion to approve the minutes from May 4, 2018. Representative Pope made a motion to accept the minutes; Mr. Orlando seconded it.
- E. Attendance/Additional Meetings.** Mr. McKay asked the members which day of the week was best for the meeting; senator Mills indicated that Friday would be the best day. Dr. Becks-Moody indicated that the next meeting will take place in the spring, either on 4/26/19 or 5/3/19. Mr. McKay asked the members to look at their calendars to determine if there are any conflicts and to revisit this item later in the meeting.

### P & T Committee Overview

- A. P & T Background and Bylaws.** Dr. Wendt provided an overview of the P&T Committee history, purpose, and procedures, as well as information about the PDL and Magellan’s role. She also indicated that the new bylaws have reduced the number of P&T committee members. She further explained that, initially, all LA Medicaid lives were in Fee-For-Service (FFS); in 2012, about half of those lives moved to MCOs. As a result, the Department was no longer collecting supplemental rebates for prescriptions filled by the members who changed to MCOs. In 2015, about 95% of Medicaid lives moved to MCOs. Finally, Dr. Wendt indicated that her department has been working with other departments to address the opioid epidemic; a quantity limit of 90 mg morphine equivalent has been implemented.

### Ethics Reminder

**Code of Ethics.** Ms. Williams went over the code of ethics. Members are bound by the governmental code of ethics. All committee members are required to complete the online ethics training.

## Reports

- A. Prior Authorization Monthly Report.** Dr. Wendt stated that the list of prior authorizations, the monthly report that was there for the Fee-For-Service claims and the PDL list were all included in the member packets.

## New Business

- A. Explanation of TOP\$, Monographs and Cost Sheets.** Dr. Douiki provided an overview of the TOP\$ supplemental rebate pool that Louisiana Medicaid participates in, as well as the savings methodologies used for the state. She indicated to the members that they should have received clinical documents, in the form of Therapeutic Class Reviews or New Drug Updates. They should also have cost sheets which include relative values, instead of actual numbers, in order to comply with the privacy laws regarding rebates.
- B. Single-PDL Implementation Update.** Dr. Steele indicated that the single PDL execution plans have been paused at this time until all stakeholder concerns have been addressed. The plan will be to hold meetings weekly in November in order to address all of the outstanding issues and in order to implement the single PDL this fiscal year. Dr. Wendt stated that a great deal of work has been put into the single PDL project and a great deal of compromises were made in order to make this initiative work for all stakeholders.
- C. Therapeutic Class Reviews of Spring Drug Classes/Drug Manufacturer Testimony.** In accordance with state law and the P&T Committee's bylaws, the following provided public testimony or answered questions raised by the Committee during the Committee's review.

| Presenter          | Representing                                     | Drug/Issue            |
|--------------------|--|-----------------------|
| Doug Boudreaux     | Healthy Blue                                     | Single-PDL            |
| Dr. Michael Nelson | Sunovion   | Latuda                |
| Nick Casale        | Indivior   | Perseris              |
| Jason Swartz       | Otsuka   | Rexulti               |
| Anthony Germade    | National Alliance on Mental Illness<br>Louisiana | Antipsychotics        |
| Alissa Hicks       | Amgen  | Enbrel                |
| Lucy Dicharry      | Pfizer   | Xeljanz               |
| Avatar Jones       | PTC Therapeutics                                 | Emflaza               |
| Jonathan James     | Hope Charities                                   | Hemophilia            |
| Tyrone McBayne     | Shire  | Advate and Adynovate  |
| Corby Lust         | Bioverativ                                       | Eloctate and Alprolix |



|   |  |            |
|---|--|------------|
| Dr. Tammy Chrisentery-Singleton   | Louisiana Center for Bleeding and Clotting Disorders | Hemophilia |
| Michael White   | Genentech  | Hemlibra   |
| Lucy Dicharry   | Pfizer   | Eucrisa    |
| Beth Hernandez  | Intersect ENT  | Sinuva     |
| **NOTE: Names of speakers who were present and yielded their time back were not captured. |  |            |

### Alzheimer's Agents

Mr. Orlando made the motion to accept. Dr. Donald seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- DONEPEZIL ODT (ORAL)
- DONEPEZIL TABLET (ORAL)
- MEMANTINE TABLET (AG) (ORAL)
- MEMANTINE TABLET (ORAL)
- RIVASTIGMINE (TRANSDERM.)

### Antidepressants, Other

Mr. Orlando made the motion to accept. Dr. Mushatt seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- BUPROPION (ORAL)
- BUPROPION SR (ORAL)
- BUPROPION XL (ORAL)
- MIRTAZAPINE ODT (ORAL)
- MIRTAZAPINE TABLET (ORAL)
- TRAZODONE (ORAL)
- VENLAFAXINE (ORAL)
- VENLAFAXINE ER CAPSULES (ORAL)

### Antidepressants, SSRI

Mr. Orlando made the motion to accept. Dr. Comeau seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- CITALOPRAM SOLUTION (ORAL)
- CITALOPRAM TABLET (ORAL)
- ESCITALOPRAM TABLET (ORAL)
- FLUOXETINE CAPSULE (ORAL)
- FLUOXETINE SOLUTION (ORAL)
- FLUVOXAMINE (ORAL)
- PAROXETINE TABLET (ORAL)
- SERTRALINE CONC (ORAL)
- SERTRALINE TABLET (ORAL)

### Antihistamines, Minimally Sedating

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- CETIRIZINE SOLUTION (ORAL)
- CETIRIZINE SOLUTION OTC (ORAL)
- CETIRIZINE TABLETS OTC (ORAL)
- LEVOCETIRIZINE TABLETS (ORAL)
- LORATADINE ODT OTC (ORAL)
- LORATADINE SOLUTION OTC (ORAL)
- LORATADINE TABLETS OTC (ORAL)

### Antihypertensives, Sympatholytics

Mr. Orlando made the motion to accept. Dr. Comeau seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- CATAPRES-TTS (TRANSDERM)
- CLONIDINE (ORAL)
- GUANFACINE (ORAL)
- METHYLDOPA (ORAL)

### Antihyperuricemics

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- ALLOPURINOL (ORAL)
- COLCHICINE CAPSULE (AG) (ORAL)
- PROBENECID (ORAL)
- PROBENECID / COLCHICINE (ORAL)

### Antiparkinson's Agents

Mr. Orlando made the motion to accept. Dr. Mushatt seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- AMANTADINE CAPSULE (ORAL)
- AMANTADINE SYRUP (ORAL)
- BENZTROPINE (ORAL)
- CARBIDOPA / LEVODOPA (ORAL)
- CARBIDOPA / LEVODOPA ER (ORAL)
- CARBIDOPA/LEVODOPA/ENTACAPONE (ORAL)
- PRAMIPEXOLE (ORAL)
- ROPINIROLE (ORAL)
- SELEGILINE CAPSULE (ORAL)
- SELEGILINE TABLET (ORAL)
- TRIHEXYPHENIDYL ELIXIR (ORAL)
- TRIHEXYPHENIDYL TABLET (ORAL)

### Antipsoriatics, Oral

Dr. Comeau made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- ACITRETIN (AG) (ORAL)
- ACITRETIN (ORAL)

### Antipsoriatics, Topical

Senator Mills made the motion to accept. Dr. Mushatt seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- CALCIPOTRIENE CREAM (TOPICAL)
- CALCIPOTRIENE SOLUTION (TOPICAL)

### Antipsychotics

Mr. Orlando made the motion to accept. Dr. Donald seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- |                                       |                                 |
|---------------------------------------|---------------------------------|
| • ABILIFY MAINTENA (INTRAMUSC.)       | • LOXAPINE (ORAL)               |
| • AMITRIPTYLINE / PERPHENAZINE (ORAL) | • OLANZAPINE ODT (ORAL)         |
| • ARIPIPIRAZOLE TABLET (ORAL)         | • OLANZAPINE TABLET (ORAL)      |
| • ARISTADA (INTRAMUSC)                | • PERPHENAZINE (ORAL)           |
| • ARISTADA INITIO (INTRAMUSC)         | • PIMOZIDE (ORAL)               |
| • CHLORPROMAZINE (ORAL)               | • QUETIAPINE ER (AG) (ORAL)     |
| • CLOZAPINE (ORAL)                    | • QUETIAPINE ER (ORAL)          |
| • FLUPHENAZINE DECANOATE (INJECTION)  | • QUETIAPINE TABLETS (ORAL)     |
| • FLUPHENAZINE TABLET (ORAL)          | • RISPERDAL CONSTA (INTRAMUSC.) |
| • GEODON (INTRAMUSC)                  | • RISPERIDONE SOLUTION (ORAL)   |
| • HALOPERIDOL (ORAL)                  | • RISPERIDONE TABLET (ORAL)     |
| • HALOPERIDOL DECANOATE (INJECTION)   | • THIORIDAZINE (ORAL)           |
| • HALOPERIDOL LACTATE (INJECTION)     | • THIOTHIXENE (ORAL)            |
| • HALOPERIDOL LACTATE CONC (ORAL)     | • TRIFLUOPERAZINE (ORAL)        |
| • INVEGA SUSTENNA (INTRAMUSC)         | • ZIPRASIDONE CAPSULE (ORAL)    |
| • INVEGA TRINZA (INTRAMUSC)           |                                 |

### Anxiolytics

Mr. Orlando made the motion to accept. Dr. Donald seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- ALPRAZOLAM TABLET (ORAL)
- BUSPIRONE (ORAL)
- LORAZEPAM TABLET (ORAL)

### **Bile Salts**

Mr. Orlando made the motion to accept. Dr. Comeau seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- URSODIOL TABLET (ORAL)

### **Bronchodilators, Beta Agonist**

Mr. Orlando made the motion to accept. Dr. Comeau seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- ALBUTEROL NEB SOLN 0.63, 1.25 MG (INHALATION)
- ALBUTEROL NEB SOLN 100 MG/20 ML (INHALATION)
- ALBUTEROL NEB SOLN 2.5 MG/0.5 ML (INHALATION)
- ALBUTEROL NEB SOLN 2.5 MG/3 ML (INHALATION)
- ALBUTEROL SYRUP (ORAL)
- PROAIR HFA (INHALATION)
- PROVENTIL HFA (INHALATION)
- SEREVENT (INHALATION)
- TERBUTALINE (ORAL)

### **Colony Stimulating Factors – New**

Dr. Donald made the motion to accept. Dr. Comeau seconded the motion. There was no objection to the motion.

- FULPHILA (SUBCUTANEOUS)
- GRANIX (INJECTION)
- NEUPOGEN DISP SYRIN (INJECTION)
- NEUPOGEN VIAL (INJECTION)

### **COPD Agents**

Mr. Orlando made the motion to accept. Representative Pope seconded the motion. There was no objection to the motion.



*Committee recommendations for the PDL are:*

- ATROVENT HFA (INHALATION)
- BEVESPI AEROSPHERE (INHALATION)
- COMBIVENT RESPIMAT (INHALATION)
- IPRATROPIUM / ALBUTEROL (INHALATION)
- IPRATROPIUM NEBULIZER (INHALATION)
- SPIRIVA (INHALATION)
- STIOLTO RESPIMAT (INHALATION)

### **Cytokine and CAM Antagonists**

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- COSENTYX PEN INJECTER (SUBCUTANE.)
- COSENTYX SYRINGE (SUBCUTANE.)
- HUMIRA KIT (INJECTION)
- HUMIRA PEN KIT (INJECTION)

### **Emollients**

Mr. Orlando made the motion to accept. Dr. Comeau seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- AMMONIUM LACTATE CREAM/LOTION (TOPICAL)

### **Epinephrine, Self-Injected**

Mr. Orlando made the motion to accept. Dr. Comeau seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- EPINEPHRINE 0.15 MG (EPIPEN JR) (AG) (INJECTION)
- EPINEPHRINE 0.3 MG (EPIPEN) (AG) (INJECTION)

### **Erythropoiesis Stimulating Proteins**

Mr. Orlando made the motion to accept. Dr. Donald seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- PROCIT (INJECTION)
- RETACRIT (INJECTION)

#### **Glucocorticoids, Inhaled**

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- ADVAIR DISKUS (INHALATION)
- ASMANEX (INHALATION)
- BUDESONIDE 0.25, 0.5 MG RESPULES (INHALATION)
- BUDESONIDE 1 MG RESPULES (INHALATION)
- DULERA (INHALATION)
- FLOVENT HFA (INHALATION)
- SYMBICORT (INHALATION)

#### **Glucocorticoids, Oral – NEW**

Dr. Comeau made the motion to accept. Mr. Orlando seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- BUDESONIDE EC (ORAL)
- DEXAMETHASONE TABLET (ORAL)
- HYDROCORTISONE (ORAL)
- METHYLPREDNISOLONE TAB DS PK (ORAL)
- PREDNISOLONE SODIUM PHOSPHATE (ORAL)
- PREDNISOLONE SOLUTION (ORAL)
- PREDNISON TABLET (ORAL)

#### **Hemophilia Treatment- New**

Mr. Orlando made the motion to accept. Dr. Donald seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- ADVATE (INTRAVEN.)
- ALPHANATE (INTRAVEN.)
- BENEFIX KIT (INTRAVEN.)
- COAGADEX (INTRAVEN)
- CORIFACT KIT (INTRAVEN)
- HUMATE-P KIT (INTRAVEN.)
- MONOCLATE-P KIT (INTRAVEN.)
- MONONINE KIT (INTRAVEN.)
- NOVOEIGHT (INTRAVEN)
- NOVOSEVEN RT (INTRAVEN)
- NUWIQ (INTRAVEN)
- PROFILNINE SD (INTRAVEN)
- RECOMBINATE (INTRAVEN.)
- WILATE (INTRAVEN)
- XYNTHA KIT (INTRAVEN)
- XYNTHA SOLOFUSE SYRINGE KIT (INTRAVEN.)

### **Histamine II Receptor Blockers**

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- FAMOTIDINE TABLET (ORAL)
- RANITIDINE SYRUP (ORAL)
- RANITIDINE TABLET (ORAL)

### **Immunomodulators, Atopic Dermatitis**

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- ELIDEL (TOPICAL)

### **Immunomodulators, Topical**

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- IMIQUIMOD (ALDARA) (TOPICAL)

### **Intranasal Rhinitis Agents**

Mr. Orlando made the motion to accept. Dr. Comeau seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- AZELASTINE (ASTELIN) (NASAL)
- AZELASTINE (ASTEPRO) (AG) (NASAL)
- AZELASTINE (ASTEPRO) (NASAL)
- FLUTICASONE (NASAL)
- IPRATROPIUM (NASAL)

### **Leukotriene Modifiers**

Mr. Orlando made the motion to accept. Dr. Comeau seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- MONTELUKAST CHEWABLE TABLET (ORAL)
- MONTELUKAST TABLET (ORAL)

### **Neuropathic Pain**

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- DULOXETINE (CYMBALTA) (ORAL)
- GABAPENTIN CAPSULE (ORAL)
- GABAPENTIN SOLUTION (ORAL)
- GABAPENTIN TABLET (ORAL)
- LIDOCAINE (AG) (TOPICAL)
- LIDOCAINE (TOPICAL)

### **NSAIDS**

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.



*Committee recommendations for the PDL are:*

- DICLOFENAC SODIUM (ORAL)
- DICLOFENAC SR (ORAL)
- IBUPROFEN SUSPENSION (ORAL)
- IBUPROFEN TABLET (ORAL)
- INDOMETHACIN CAPSULE (ORAL)
- KETOROLAC (ORAL)
- MELOXICAM TABLET (ORAL)
- NABUMETONE (ORAL)
- NAPROXEN EC (ORAL)
- NAPROXEN SUSPENSION (ORAL)
- NAPROXEN TABLET (ORAL)
- SULINDAC (ORAL)
- VOLTAREN (TOPICAL)

### **Oncology, Oral – Breast – New**

Dr. Donald made the motion to accept. Mr. Orlando seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- ANASTROZOLE (ORAL)
- CYCLOPHOSPHAMIDE (ORAL)
- EXEMESTANE (ORAL)
- IBRANCE (ORAL)
- LETROZOLE (ORAL)
- TAMOXIFEN CITRATE (ORAL)
- XELODA (ORAL)

### **Oncology, Oral - Hematologic – New**

Dr. Donald made the motion to accept. Dr. Comeau seconded the motion. Dr. Comeau made the motion to add Tretinoin (Oral) as preferred on the PDL. After discussion and unanimous vote, there was no objection to the motion.

*Committee recommendations for the PDL are:*

- GLEEVEC (ORAL)
- HYDROXYUREA (ORAL)
- IMBRUVICA CAPSULE (ORAL)
- IMBRUVICA TABLET (ORAL)
- JAKAFI (ORAL)
- LEUKERAN (ORAL)
- MELPHALAN (ORAL)
- MERCAPTOPYRINE (ORAL)
- MYLERAN (ORAL)
- REVLIMID (ORAL)
- SPRYCEL (ORAL)
- TASIGNA (ORAL)

- MATULANE (ORAL)
- TRETINOIN (ORAL)

### **Oncology, Oral – Lung – New**

Dr. Comeau made the motion to accept. Dr. Donald seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- ALECENSA (ORAL)
- GILOTRIF (ORAL)
- HYCAMTIN (ORAL)
- IRESSA (ORAL)
- TAGRISSO (ORAL)
- TARCEVA (ORAL)
- XALKORI (ORAL)

### **Oncology, Oral – Other – New**

Dr. Comeau made the motion to accept. Mr. Donald seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- CAPRELSA (ORAL)
- GLEOSTINE (ORAL)
- TEMOZOLOMIDE (AG) (ORAL)
- TEMOZOLOMIDE (ORAL)

### **Oncology, Oral – Prostate – New**

Dr. Donald made the motion to accept. Dr. Comeau seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- BICALUTAMIDE (ORAL)
- FLUTAMIDE (ORAL)

### **Oncology, Oral - Renal Cell – New**

Mr. Orlando made the motion to accept. Dr. Donald seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- INLYTA (ORAL)
- LENVIMA (ORAL)
- NEXAVAR (ORAL)
- SUTENT (ORAL)
- VOTRIENT (ORAL)

#### **Oncology, Oral – Skin – New**

Mr. Orlando made the motion to accept. Dr. Comeau seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- COTELLIC (ORAL)
- ERIVEDGE (ORAL)
- MEKINIST (ORAL)
- ODOMZO (ORAL)
- TAFINLAR (ORAL)
- ZELBORAF (ORAL)

#### **Ophthalmic Antibiotic/Steroid Combinations**

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- NEOMYCIN/POLYMYXIN/DEXAMETHASONE (OPHTHALMIC)
- SULFACETAMIDE / PREDNISOLONE (OPHTHALMIC)
- TOBRADEX OINTMENT (OPHTHALMIC)
- TOBRADEX SUSPENSION (OPHTHALMIC)

#### **Ophthalmic Antibiotics**

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

Committee recommendations for the **PDL** are:

- BACITRACIN/POLYMYXIN B SULFATE OINT. (OPHTHALMIC)
- CIPROFLOXACIN SOLUTION (OPHTHALMIC)
- ERYTHROMYCIN (OPHTHALMIC)
- GENTAMICIN DROPS (OPHTHALMIC)
- GENTAMICIN OINT. (OPHTHALMIC)
- MOXEZA (OPHTHALMIC)
- NEOMYCIN-POLYMYXIN-GRAMICIDI N (OPHTHALMIC)
- OFLOXACIN (OPHTHALMIC)
- POLYMYXIN/TRIMETHOPRIM (OPHTHALMIC)
- SULFACETAMIDE SOLUTION (OPHTHALMIC)
- TOBRAMYCIN (OPHTHALMIC)

### **Ophthalmics for Allergic Conjunctivitis**

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

*Committee recommendations for the **PDL** are:*

- ALREX (OPHTHALMIC)
- CROMOLYN SODIUM (OPHTHALMIC)
- OLOPATADINE (PATANOL) (AG) (OPHTHALMIC)
- OLOPATADINE (PATANOL) (OPHTHALMIC)
- PAZEO (OPHTHALMIC)

### **Ophthalmic Anti-inflammatories**

Mr. Orlando made the motion to accept. Representative Pope seconded the motion. There was no objection to the motion.

*Committee recommendations for the **PDL** are:*



- DEXAMETHASONE (OPHTHALMIC)
- DICLOFENAC (OPHTHALMIC)
- DUREZOL (OPHTHALMIC)
- FLUOROMETHOLONE (OPHTHALMIC)
- FLURBIPROFEN (OPHTHALMIC)
- ILEVRO (OPHTHALMIC)
- KETOROLAC (OPHTHALMIC)
- KETOROLAC LS (OPHTHALMIC)
- PREDNISOLONE ACETATE (OPHTHALMIC)

### Ophthalmics, Anti-Inflammatory/Immunomodulator

Mr. Orlando made the motion to accept. Representative Pope seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- RESTASIS (OPHTHALMIC)
- RESTASIS MULTIDOSE (OPHTHALMIC)

### Ophthalmics, Glaucoma Agents

Mr. Orlando made the motion to accept. Representative Pope seconded the motion. There was no objection to the motion.

Committee recommendations for the PDL are:

- |                                      |                                  |
|--------------------------------------|----------------------------------|
| • ALPHAGAN P 0.15% (OPHTHALMIC)      | • LEVOBUNOLOL (OPHTHALMIC)       |
| • BRIMONIDINE (OPHTHALMIC)           | • PILOCARPINE (OPHTHALMIC)       |
| • CARTEOLOL (OPHTHALMIC)             | • RHOPRESSA (OPHTHALMIC)         |
| • COMBIGAN (OPHTHALMIC)              | • SIMBRINZA (OPHTHALMIC)         |
| • DORZOLAMIDE (OPHTHALMIC)           | • TIMOLOL (OPHTHALMIC)           |
| • DORZOLAMIDE / TIMOLOL (OPHTHALMIC) | • TRAVATAN Z 2.5 ML (OPHTHALMIC) |
| • LATANOPROST 2.5 ML (OPHTHALMIC)    | • TRAVATAN Z 5 ML (OPHTHALMIC)   |

### Otic Anti-infectives & Anesthetics

Mr. Orlando made the motion to accept. Representative Pope seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- ACETIC ACID (OTIC)
- ACETIC ACID HC (OTIC)

### **Otic Antibiotics**

Mr. Orlando made the motion to accept. Representative Pope seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- CIPRODEX (OTIC)
- CIPROFLOXACIN (OTIC)
- NEOMYCIN/POLYMYXIN/HC SOLN/SUSP (OTIC)

### **Progestational Agents**

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- HYDROXYPROGESTERONE CAPROATE VIAL (AG) (INTRAMUSCULAR)
- HYDROXYPROGESTERONE CAPROATE VIAL (INTRAMUSCULAR)
- MAKENA AUTO INJECTOR (SUBCUTANEOUS)
- MAKENA MDV (INTRAMUSC)
- MAKENA SDV (INTRAMUSC)
- MEDROXYPROGESTERONE ACETATE (ORAL)
- NORETHINDRONE ACETATE (ORAL)
- PROGESTERONE CAPSULE (ORAL)

### **Sedative Hypnotics**

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- TEMAZEPAM (ORAL)
- TRIAZOLAM (ORAL)
- ZOLPIDEM (ORAL)

### **Smoking Cessation**

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- BUPROPION SR (ORAL)
- CHANTIX (ORAL)
- CHANTIX DOSE PACK (ORAL)
- NICOTINE GUM OTC (BUCCAL)
- NICOTINE LOZENGE OTC (BUCCAL)
- NICOTINE PATCH OTC (TRANSDERMAL)

### **Steroids Topical, High**

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- BETAMET DIPROP / PROP GLY CREAM (TOPICAL)
- BETAMETHASONE VALERATE CREAM (TOPICAL)
- BETAMETHASONE VALERATE LOTION (TOPICAL)
- BETAMETHASONE VALERATE OINTMENT (TOPICAL)
- TRIAMCINOLONE ACETONIDE CREAM (TOPICAL)
- TRIAMCINOLONE ACETONIDE LOTION (TOPICAL)
- TRIAMCINOLONE ACETONIDE OINTMENT (TOPICAL)

### **Steroids Topical, Low**

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- DERMA-SMOOTH-FS (TOPICAL)
- HYDROCORTISONE CREAM (TOPICAL)
- HYDROCORTISONE LOTION (TOPICAL)
- HYDROCORTISONE OINTMENT (TOPICAL)

### **Steroids Topical, Medium**

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- FLUTICASONE PROPIONATE CREAM (TOPICAL)
- FLUTICASONE PROPIONATE OINTMENT (TOPICAL)
- MOMETASONE FUROATE CREAM (TOPICAL)
- MOMETASONE FUROATE OINTMENT (TOPICAL)
- MOMETASONE FUROATE SOLUTION (TOPICAL)

### **Steroids Topical, Very High**

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- CLOBETASOL EMOLLIENT (TOPICAL)
- CLOBETASOL PROPIONATE CREAM (TOPICAL)
- CLOBETASOL PROPIONATE GEL (TOPICAL)
- CLOBETASOL PROPIONATE OINTMENT (TOPICAL)
- CLOBETASOL PROPIONATE SOLUTION (TOPICAL)
- HALOBETASOL PROPIONATE CREAM (TOPICAL)
- HALOBETASOL PROPIONATE OINTMENT (TOPICAL)

### **Stimulants and Related Agents**

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- AMPHETAMINE SALT COMBO (ORAL)
- AMPHETAMINE SALT COMBO ER (AG) (ORAL)
- AMPHETAMINE SALT COMBO ER (ORAL)
- APTENSIO XR (ORAL)
- ATOMOXETINE (AG) (ORAL)
- ATOMOXETINE (ORAL)
- DEXMETHYLPHENIDATE (AG) (ORAL)
- DEXMETHYLPHENIDATE (ORAL)
- DEXTROAMPHETAMINE TABLET (ORAL)
- FOCALIN XR (ORAL)
- METHYLPHENIDATE CD (AG) (ORAL)
- METHYLPHENIDATE CD (ORAL)
- METHYLPHENIDATE ER (CONCERTA) (AG) (ORAL)
- METHYLPHENIDATE ER (CONCERTA) (ORAL)
- METHYLPHENIDATE ER (RITALIN LA) (ORAL)
- MODAFINIL (ORAL)
- PROCENTRA (ORAL)
- QUILLICHEW ER (ORAL)
- QUILLIVANT XR (ORAL)
- VYVANSE CAPSULE (ORAL)



- GUANFACINE ER (ORAL)
- METHYLPHENIDATE (ORAL)
- VYVANSE CHEWABLE TABLET (ORAL)

## II. Single Drug Reviews

In accordance with state law and the P&T Committee’s bylaws, the following provided public testimony or answered questions raised by the Committee during the Committee’s review.

| Presenter   | Representing | Drug/Issue |
|---|--------------|------------|
| Christopher Cant  | Allergan     | Byvalson   |
| **NOTE: Names of speakers who were present and yielded their time back were not captured. |              |            |

The single drugs were reviewed and a recommendation was made; P&T Committee recommendations follow:

### Analgesics, Narcotics Short

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- ROXYBOND (ORAL) – NPD

### Androgenic Agents

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- TESTOSTERONE GEL (AG) (VOGELXO) (TRANSDERM)– preferred
- TESTOSTERONE GEL (VOGELXO) (TRANSDERM) –preferred
- TESTOSTERONE GEL PACKET (AG) (ANDROGEL) (TRANSDERM) - preferred
- TESTOSTERONE GEL PACKET (ANDROGEL) (TRANSDERM) - preferred
- ANDROGEL GEL PACKET (TRANSDERM.) - NPD
- ANDROGEL GEL PUMP (TRANSDERM) - NPD

### Antibiotics, Inhaled

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- TOBRAMYCIN PAK (AG) (INHALATION) –preferred
- KITABIS PAK (INHALATION) –NPD

### **Anticoagulants**

Dr. Donald made the motion to accept. Mr. Orlando seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- ENOXAPARIN SODIUM VIAL (AG) (SUBCUTANEOUS) –preferred
- LOVENOX VIAL (SUBCUTANE.) –NPD

### **Antiemetic/Antivertigo Agents**

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- APREPITANT CAPSULE (ORAL) – preferred
- AKYNZEO (INTRAVEN) –NPD
- EMEND CAPSULE (ORAL) - NPD

### **Antimigraine Agents, Triptans**

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- SUMATRIPTAN (NASAL) –preferred
- IMITREX (NASAL) –NPD

### **Antiparasitics, Topical**

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- CROTAN (TOPICAL)– NPD

### **Antivirals, Oral**

Dr. Mushatt made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- ACYCLOVIR SUSPENSION (ORAL) –preferred
- OSELTAMIVIR SUSPENSION (ORAL) - preferred
- TAMIFLU SUSPENSION (ORAL) –NPD
- ZOVIRAX SUSPENSION (ORAL) - NPD

### Beta-Blockers

Dr. Bachhuber made the motion to accept. Dr. Donald seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- KAPSPARGO (ORAL)– NPD

### Cephalosporins And Related Antibiotics

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- DAXBIA (ORAL)– recommend NPD

### Hypoglycemics, Insulin And Related Agents

Mr. Orlando made the motion to accept. Representative Pope seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- TOUJEO MAX SOLOSTAR PEN (SUBCUTANEOUS) –NPD

### Lipotropics, Statins

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- ZYPITAMAG (ORAL) – NPD

### Platelet Aggregation Inhibitors

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- ASPIRIN/DIPYRIDAMOLE (AG) (ORAL) –preferred
- ASPIRIN/DIPYRIDAMOLE (ORAL) –preferred
- AGGRENOX (ORAL) – NPJ

### Proton Pump Inhibitors

Mr. Orlando made the motion to accept. Dr. Bachhuber seconded the motion. There was no objection to the motion.

*Committee recommendations for the PDL are:*

- ESOMEPRAZOLE KIT (ORAL) –NPJ

### Other Business


Dr. Wendt thanked the committee members for their service.

### Next Steps

- Proposed Therapeutic Classes to be Reviewed at Next Meeting.** Therapy classes to be reviewed for the spring 2019 meeting will be posted on the DHH Medicaid Pharmacy and Therapeutics Committee page as "Agenda."
- Next Meeting Date.** The next committee meeting is scheduled for April 26, 2019 or May 3, 2019.
- Public Testimony.** None.

### Adjournment

The meeting adjourned at or about 1:02 p.m.

  
Marty McKay, P&T Committee Chairman

Marty McKay 4/26/19